BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Medivation, Inc. 

201 Spear Street
3rd Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


View Clinical Trials from BioPharm Insight

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at

 Key Statistics


Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN


Pfizer Inc. 

 Company News
Medivation, Inc. (MDVN) Reports Second Quarter Financial Results And Provides Corporate Update 8/8/2014 10:27:43 AM
Medivation, Inc. (MDVN) Announces Second Quarter 2014 Financial Results Teleconference On August 7, 2014 7/25/2014 9:27:00 AM
Medivation, Inc. (MDVN) Announces Change In Executive Management Team 7/11/2014 10:22:10 AM
Medivation, Inc. (MDVN) Again Voted Among Top Workplaces In The SF Bay Area 6/17/2014 12:26:22 PM
Medivation, Inc. (MDVN) Founder, President and Chief Executive Officer David Hung, M.D. Named An EY Entrepreneur Of The Year™ 2014 Award Winner In Northern California 6/12/2014 10:20:50 AM
Medivation, Inc. (MDVN) Release: The New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy 6/2/2014 10:46:45 AM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conferences 5/13/2014 10:02:43 AM
Medivation, Inc. (MDVN) Reports First Quarter Financial Results And Provides Corporate Update 5/9/2014 8:53:46 AM
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Receive Priority Review From FDA For XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer 5/6/2014 9:34:58 AM
Medivation, Inc. (MDVN) Announces First Quarter 2014 Financial Results Teleconference On May 8, 2014 4/25/2014 8:49:27 AM